AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that’s spread or can’t be removed by surgery.

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...